Traders Sell Shares of Zoetis Inc. (ZTS) on Strength (ZTS)
Traders sold shares of Zoetis Inc. (NYSE:ZTS) on strength during trading hours on Tuesday. $24.78 million flowed into the stock on the tick-up and $55.90 million flowed out of the stock on the tick-down, for a money net flow of $31.12 million out of the stock. Of all equities tracked, Zoetis had the 0th highest net out-flow for the day. Zoetis traded up $0.03 for the day and closed at $51.29
ZTS has been the topic of several recent research reports. Stifel Nicolaus initiated coverage on Zoetis in a research note on Tuesday, May 31st. They issued a “buy” rating and a $58.00 price target on the stock. Guggenheim reaffirmed a “positive” rating and issued a $60.00 price target on shares of Zoetis in a research note on Monday, August 22nd. Jefferies Group reaffirmed a “buy” rating and issued a $60.00 price target on shares of Zoetis in a research note on Tuesday, August 23rd. Citigroup upped their price target on Zoetis from $50.00 to $53.00 and gave the stock a “neutral” rating in a research note on Thursday, August 4th. Finally, Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a research note on Wednesday, June 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Zoetis has a consensus rating of “Buy” and an average target price of $54.79.
The firm has a market cap of $25.39 billion and a P/E ratio of 39.95. The company’s 50 day moving average is $50.95 and its 200-day moving average is $47.13.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/07/traders-sell-shares-of-zoetis-inc-zts-on-strength-zts.html
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.05. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the business posted $0.43 earnings per share. Zoetis’s revenue was up 2.8% on a year-over-year basis. Equities analysts predict that Zoetis Inc. will post $1.90 EPS for the current fiscal year.
In other Zoetis news, Director Michael B. Mccallister purchased 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was purchased at an average cost of $51.34 per share, with a total value of $102,680.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Andrew Fenton sold 13,870 shares of the firm’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $51.25, for a total value of $710,837.50. Following the sale, the insider now directly owns 17,719 shares of the company’s stock, valued at $908,098.75. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Zoetis stock. Schwab Charles Investment Management Inc. increased its stake in Zoetis Inc. (NYSE:ZTS) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,491,364 shares of the company’s stock after buying an additional 31,045 shares during the period. Schwab Charles Investment Management Inc. owned about 0.30% of Zoetis worth $71,467,000 at the end of the most recent quarter.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.